The core activity of Santersus AG is the development and application of Therapeutic Apheresis technologies, particularly for the treatment of diseases such as sepsis, cancer, autoimmune diseases, COVID-19 and transplantation. The company focuses on the development of devices and applications for blood purification and treatment.
AI-generated
Offering
Products & services
Industry:Medical Technology Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Therapeutic apheresis for the selective extracorporeal removal of neutrophil extracellular traps (NETs) from blood, integrable into existing plasmapheresis and sepsis treatment protocols.
NucleoCapture apheresis device
Selective apheresis device for the removal of circulating NETs and other cell-free DNA fragments from blood; developed as a blood purification technology for therapeutic applications.
Treatments for sepsis and autoimmune diseases
NET-targeted therapies for sepsis, lupus (SLE) and other autoimmune diseases; clinical development with reference to critical care and first feasibility data.
Therapies for transplant indications
NET-targeted therapies for lung transplantation and liver transplantation in the clinical pipeline program, as additional follow-on indications of the apheresis technology.
Diagnostic cell-free DNA extraction
In vitro diagnostic (IVD) microdevice for extraction of cell-free DNA for liquid biopsy and non-invasive prenatal tests; based on NucleoCapture technology.
Knowledge
No knowledge articles yet
Once SANTERSUS AG has claimed this profile, we'll publish editorial articles and case studies here together.